Health
Regeneron halts trial of antibody treatment in seriously ill Covid patients – Financial Times
Drug hailed as coronavirus ‘cure’ by Donald Trump will still be studied in mild-to-moderate cases
Regeneron has stopped enrolling seriously ill Covid-19 patients in a clinical trial of the antibody treatment that US President Donald Trump has hailed as a “cure” for the disease.
Shares in Regeneron fell as much as 3 per cent after an independent data monitoring committee warned that the risks might outweigh the benefits for hospitalised patients on high levels of oxygen.
The move comes after Eli Lilly, which is also developing a Covid-19 antibody treatment, stopped its trial in hospitalised…
-
General13 hours agoBritish and US planes fly 12-hour mission to patrol Russian border
-
Noosa News17 hours agoWarm weather could make way for rain with ‘damaging winds, large hail’
-
General16 hours agoYoung boy flown to Brisbane hospital after K’gari dingo attack
-
Noosa News23 hours agoBrisbane muralist explains why he ended his plan to eat one chicken a day for a year